Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
|Articles|February 26, 2010
VCF Homepage copy
The Virtual Career Expo is a great way to advance your career without leaving the comfort of your home or office.
Advertisement
Now available on demand!
• Visit exhibitor booths and view their job listings.
• View audio and video presentations about prospective positions.
• Post your profile and resume so that recruiters can reach out to you.
• Apply immediately for available positions and start the interview process.
Register Now
Enter Event
Advertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
4
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
5